10-K: Avanos Medical Reports Reduced Loss Amid Strategic Shift

Avanos Medical, Inc. reported a significantly reduced net loss in 2025, driven by strategic acquisitions and divestitures, despite ongoing restructuring costs and a goodwill impairment.

Summary

• Avanos Medical, Inc. reported a net loss of $72.9 million for the year ended December 31, 2025, a substantial improvement from the $392.1 million net loss in 2024.
• Total net sales increased by 1.9% to $701.2 million in 2025, compared to $687.8 million in 2024.
• Specialty Nutrition Systems (SNS) net sales grew 9.2% to $432.9 million, primarily due to strong demand for enteral feeding and neonate solutions, including contributions from the Nexus acquisition.
• Pain Management and Recovery (PM&R) net sales increased 1.5% to $237.8 million, with Radiofrequency Ablation (RFA) solutions growing 10.1%, partially offset by an 8.5% decline in surgical pain and recovery products.
• The company recorded a goodwill impairment charge of $77.0 million in 2025 for the PM&R reporting unit, a significant reduction from the $436.7 million impairment in 2024.
• Avanos acquired Nexus Medical, LLC for $27.0 million (plus up to $20.0 million in contingent consideration) in September 2025, enhancing its SNS portfolio.
• The company divested its HA product line and Game Ready rental business in 2025 as part of its ongoing Transformation Process.
• Restructuring costs related to the Transformation Process amounted to $32.4 million in 2025, with an additional $10.0 million in incremental expenses expected in 2026, aiming for $15.0 million to $20.0 million in annualized savings.
• Operating cash flow for 2025 was $74.7 million, down from $100.7 million in 2024.
• Long-term debt, net, decreased to $90.3 million as of December 31, 2025, from $125.3 million in 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing with a neutral sentiment. While the company demonstrated significant improvement in reducing its net loss and achieved positive sales growth in core segments, ongoing restructuring costs, a continued net operating loss, and external risks like potential Medicare reimbursement changes for RFA temper a more positive outlook.

Positives

• Net loss significantly reduced to $72.9 million in 2025 from $392.1 million in 2024, indicating an improvement in financial performance.
• Total net sales increased by 1.9% to $701.2 million in 2025, demonstrating overall revenue growth.
• Specialty Nutrition Systems (SNS) net sales grew strongly by 9.2% to $432.9 million, driven by demand for enteral feeding and neonate solutions.
• Neonate solutions experienced above-market growth, bolstered by the recently acquired Nexus TKO offerings.
• Radiofrequency Ablation (RFA) solutions net sales increased by 10.1%, reflecting higher RFA generator sales and procedures.
• Goodwill impairment charge decreased substantially to $77.0 million in 2025 from $436.7 million in 2024.
• Selling and general expenses decreased from $318.5 million in 2024 to $315.6 million in 2025, attributed to savings from the Transformation Process and increased spending discipline.
• Successfully completed the Nexus Acquisition for $27.0 million, expanding the SNS portfolio into the vascular access market and increasing relevance with current customers.
• Divested non-core assets, including the HA product line and Game Ready rental business, aligning with the strategic focus on SNS and PM&R segments.
• Operating cash flow remained positive at $74.7 million in 2025.
• Reduced long-term debt from $125.3 million in 2024 to $90.3 million in 2025.
• The U.S. Department of Justice's case related to MicroCool surgical gowns was dismissed in January 2025, resolving a long-standing legal matter.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• The company reported a net loss of $72.9 million and an operating loss of $61.6 million in 2025, indicating continued unprofitability.
• Surgical pain and recovery net sales decreased by 8.5% due to lower volume and the strategic decision to exit certain revenue streams.
• Cost of products sold increased to $347.3 million in 2025, primarily due to increased tariffs and unfavorable pricing for exited product lines.
• Research and development costs decreased from $26.2 million in 2024 to $23.3 million in 2025, potentially signaling reduced investment in future innovation.
• Cash and cash equivalents decreased by $17.9 million to $89.8 million as of December 31, 2025.
• Operating cash flow decreased from $100.7 million in 2024 to $74.7 million in 2025.
• The company incurred $32.4 million in restructuring costs in 2025, with up to an additional $10.0 million expected in 2026, reflecting ongoing operational adjustments.
• A number of Medicare Administrative Contractors (MACs) have drafted a proposed coverage policy questioning the medical necessity of RFA treatment for peripheral nerve pain, with a final determination expected in early 2026, which could materially impact RFA product sales.
• The company's market capitalization decreased in the second quarter of 2025, triggering an interim goodwill impairment test.
• Avanos Medical's common stock significantly underperformed the S&P MidCap 400 Index and the S&P 500 Health Care Equipment and Services Index over the five-year period ending December 31, 2025.

Risks

• Strong competition from domestic and foreign companies, new technologies, and alternative clinical practices could materially adversely affect the business.
• Failure to successfully develop, acquire, or market competitive products and technologies, or enhance existing products, could negatively impact net sales.
• Strategic acquisitions, investments, or alliances may not be successful, requiring more resources, diverting management attention, or failing to achieve expected benefits.
• Inability to attract and retain key executives and other employees, particularly those with specialized skills, could materially adversely affect the business.
• Reliance on the proper function, security, and availability of information technology systems and data, as well as those of third parties, exposes the company to risks from failures, security breaches, and cyberattacks.
• Failure to effectively integrate AI into information technology systems and operations could result in operational inefficiencies, reputational damage, and legal liabilities.
• Inability to protect intellectual property rights or potential infringement of others' rights could lead to costly litigation, significant damage awards, or injunctions.
• Global climate change presents risks including increased operational costs, physical risks to facilities, and adverse impacts on the supply chain, manufacturing, and distribution networks.
• The failure of healthcare programs to provide coverage and reimbursement, or reductions in levels of reimbursement, could materially adversely affect the business by reducing product selection and prices.
• A potential final determination by Medicare Administrative Contractors (MACs) that RFA treatment for peripheral nerve pain is not reasonable and necessary for coverage would eliminate Medicare reimbursements for such treatments, materially affecting RFA product sales.
• A pandemic or other public health emergency could adversely impact business operations, financial condition, results of operations, and cash flows.
• An inability to obtain key components, raw materials, or manufactured products from third parties, especially single-source suppliers, may materially adversely affect the ability to manufacture or deliver products.
• An interruption in the ability to manufacture products, particularly due to concentration of operations in Mexico and single-location manufacturing, could materially adversely affect the business.
• Failure to successfully execute on or achieve the expected benefits of the three-year Transformation Process could have a material adverse impact on the business.
• Failure to fully realize the anticipated benefits of divestiture activities could have a material adverse impact on the business.
• Ongoing regional conflicts (e.g., Russia-Ukraine, Middle East) and potential conflicts (e.g., China-Taiwan) could damage international commerce, shipping, supply chains, and the global economy.
• Supply chain disruptions due to various factors (e.g., supplier constraints, pandemics, cybersecurity, military conflicts, transportation delays) could increase costs, reduce production, and delay shipments.
• Inflationary pressures on manufacturing costs, operating expenses, and customer purchasing power could adversely affect business, results of operations, and cash flows.
• Changes in tax laws and related interpretations by governmental bodies could have a material adverse effect on the business.
• Significant uncertainty in the healthcare industry due to government healthcare reform and legislative changes could lower reimbursements and adversely affect the business.
• Extensive government regulation requires significant expenses for compliance, and failure to comply could lead to manufacturing shutdowns, product recalls, or sanctions.
• Subject to healthcare fraud and abuse laws and regulations that could result in significant liability, changes in business practices, or restrictions on operations.
• The regulatory clearance process for new or modified products can be costly, time-consuming, and result in limitations on product uses.
• Manufacturing operations in Mexico are subject to risks including Maquiladora status compliance, civil unrest, criminal activity, military action, and inflationary pressures.
• Potential product liability losses, litigation liability, product recalls, safety alerts, or regulatory action could be costly and disruptive.
• Economic conditions, including financial market disruptions and recessions, could adversely affect customer purchasing decisions and ability to pay.
• Currency exchange rate fluctuations, particularly for the Canadian dollar, Mexican peso, and Euro, could have a material adverse effect on business and results of operations.
• Exposure to price fluctuations of key commodities may negatively impact results if cost increases cannot be offset by price adjustments or cost reductions.
• Cost-containment efforts of customers, healthcare purchasing groups (GPOs), third-party payors, and governmental organizations could adversely affect sales and profitability.
• Political, economic, and regulatory risks associated with doing business outside the United States, including data privacy, labor laws, tax laws, trade restrictions, and anti-bribery laws.
• Tariffs and taxes in the United States and foreign jurisdictions, and potential trade protection measures, could increase costs and disrupt supply chains.
• The need for additional financing in the future to meet capital needs or make acquisitions, which may not be available on favorable terms, if at all.
• Any non-cash impairment of long-lived assets, including intangible assets and goodwill, could have a material adverse impact on results of operations.
• The company cannot guarantee that its stock price will not decline or fluctuate significantly due to various market and company-specific factors.
• The company has no present intention to pay dividends on common stock.
• The percentage of ownership of existing stockholders may be diluted in the future due to equity issuances for acquisitions, capital market transactions, or equity awards.
• Certain provisions of the company's certificate of incorporation and Delaware law may make it difficult for stockholders to initiate litigation or change the composition of the Board of Directors, and may discourage hostile takeover attempts.

Future Outlook

The company expects its operating cash flow to be sufficient to meet working capital requirements and fund capital expenditures for the next twelve months. Initiatives associated with the expanded Transformation Process are anticipated to run through 2026, with expected annualized savings of $15.0 million to $20.0 million, though up to $10.0 million in incremental expenses are also projected for 2026. A final determination on Medicare coverage for RFA treatment for peripheral nerve pain is expected in early 2026, which could significantly impact RFA product sales. Compliance with the EU Medical Device Regulation (EU MDR) will continue to require substantial technical expertise and capital investment through its transition period ending December 31, 2027, or December 31, 2028. The company anticipates that the percentage of its net sales generated outside North America will grow over time and expects inflationary trends to persist. No cash dividends are expected in the foreseeable future.

Management Comments

• We are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery.
• The Nexus Acquisition enhanced our product offerings and is aligned with our existing call points, increasing our relevance with current customers.
• We believe that our key product characteristics, such as proven efficacy, reliability and safety, along with our product launch capability, efficient manufacturing processes, education and training, and our established distribution network, field sales organization and customer service group, are important factors that distinguish us from our competitors.
• Employees are our most-valued resource and are at the center of everything we do. Their talent, diversity and commitment are crucial to our innovation and success.
• Our goal is to ensure that each of our more than 2,200 employees understands how they contribute to the Company's innovation and growth.
• We are working to expand our use of AI to drive efficiencies and enhance productivity, including in the areas of finance, procurement, marketing and IT support.
• We believe that the ultimate resolution of any pending legal proceeding to which we are a party will not have a material adverse effect on our business, financial condition, results of operations or liquidity.

Industry Context

StockSavvy.ai notes that the medical technology industry remains highly competitive, characterized by continuous innovation and evolving regulatory landscapes, such as the EU MDR and potential changes in Medicare reimbursement policies. The sector is also grappling with global supply chain disruptions, inflationary pressures, and the increasing adoption of advanced technologies like AI for operational efficiencies. Cost-containment efforts by healthcare providers and group purchasing organizations continue to exert pressure on pricing and profitability across the industry.

Comparison to Industry Standards

• StockSavvy.ai notes that Avanos Medical's stock performance significantly lagged the S&P MidCap 400 Index and the S&P 500 Health Care Equipment and Services Index over the five-year period ending December 31, 2025, indicating underperformance relative to broader market and sector benchmarks.
• The company faces competition in Specialty Nutrition Systems from Boston Scientific Corporation, Cook Medical, Applied Medical Technology, Inc., and Cardinal Health.
• In Pain Management and Recovery, key competitors include Boston Scientific Corporation, Pacira Pharmaceuticals, Inc., Stryker Corporation, Medtronic plc, Pajunk Medical Systems, Stratus Medical, and Nice Recovery Systems.

Management Changes

Corporate Governance

Legal Proceedings

• The U.S. Department of Justice's criminal investigation related to MicroCool surgical gowns was dismissed in January 2025, following a $22.2 million payment in July 2021 under a Deferred Prosecution Agreement.
• The company is subject to various ongoing legal proceedings, claims, and governmental inspections pertaining to contract disputes, product liability, tax matters, patents and trademarks, advertising, governmental regulations, and employment.
• In 2023, the company incurred $10.0 million of expense for a settlement related to a customer claim; no litigation-related charges were recorded in 2024 or 2025 (a $1.4 million recovery from a 2023 customer claim settlement was recognized in 2025).
• The company operates in an industry characterized by extensive patent litigation, with potential for significant damage awards and injunctions.

Related Party Transactions

• Under the terms of the distribution agreement from the 2014 spin-off, Avanos Medical is obligated to indemnify and hold Kimberly-Clark Corporation harmless for legal proceedings, claims, and liabilities primarily related to Avanos's business. No costs were incurred for such indemnification matters in 2023, 2024, or 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances and continued stock price volatility, with no dividends expected in the foreseeable future.
• Employees are impacted by ongoing restructuring initiatives, which involve severance and benefits costs, but the company emphasizes competitive compensation, training, engagement, health, safety, and diversity.
• Customers may be affected by pricing pressures and potential changes in Medicare reimbursement for RFA treatments, while benefiting from new product offerings and the company's focus on patient outcomes.
• Suppliers, particularly single-source providers, face risks from potential supply chain disruptions, which could affect their ability to provide raw materials and components.
• Creditors are impacted by the company's debt levels and compliance with debt covenants, which were met as of December 31, 2025.

Next Steps

• A final determination on Medicare coverage for RFA treatment for peripheral nerve pain is expected in early 2026.
• Initiatives associated with the expansion of the Transformation Plan are expected to run through 2026, with up to $10.0 million of incremental expenses anticipated.
• Compliance with the EU Medical Device Regulation (EU MDR) requires re-certification of many products during a transition period ending December 31, 2027, or December 31, 2028.
• The company will adopt new accounting standards: ASU No. 2025-09 (Hedge Accounting Improvements) for fiscal years beginning after December 15, 2026; ASU No. 2025-05 (Measurement of Credit Losses) for annual periods beginning after December 15, 2025; ASU No. 2025-06 (Internal-Use Software) for annual periods beginning after December 15, 2027; and ASU No. 2024-03 (Disaggregation of Income Statement Expenses) for annual periods beginning after December 15, 2026.

Key Dates

Recommendation

Avanos Medical is in a transitional phase, evidenced by its ongoing Transformation Process, strategic acquisitions, and divestitures. While the company showed improved net loss and reduced goodwill impairment compared to the previous year, it continues to operate at a net loss. Positive sales growth in key segments like Specialty Nutrition Systems and RFA is encouraging, but the decline in surgical pain and recovery products and the potential adverse impact of Medicare reimbursement changes for RFA introduce uncertainty. The stock's significant underperformance relative to industry benchmarks suggests a cautious approach. A 'Hold' recommendation allows investors to observe the successful execution of the Transformation Process and the resolution of key risks, such as RFA reimbursement, before making a more definitive investment decision.

Keywords

Medical Technology, SEC Filing, 10-K Annual Report, Avanos Medical, AVNS, Specialty Nutrition Systems, Pain Management and Recovery, Enteral Feeding, Neonate Solutions, Radiofrequency Ablation, RFA, Goodwill Impairment, Restructuring, Transformation Process, Acquisitions, Divestitures, Financial Performance, Net Sales, Operating Loss, Cash Flow, Debt, Corporate Governance, Risk Factors, Cybersecurity, Regulatory Compliance, EU MDR, Medicare Reimbursement, Supply Chain, Inflation, Intellectual Property, Executive Changes